Sydney, Australia (April 8, 2016) – SpeeDx Pty, Ltd. today announced that it will feature its PlexPCR™ for detection of infectious disease pathogens and the unique ResistancePlus™ multiplex qPCR test for detection of M. genitalium and antimicrobial resistance markers1 at the ECCMID 2016 Congress in Amsterdam, the Netherlands, 9-12 April 2016. More information will be available at Booth 103.
SpeeDx at ECCMID
- ePoster #EV0547 by Dr. Elisa Mokany: Multiplex detection of antibiotic resistance using new qPCR technology
- Paper poster #P0930 by Dr. Sepehr Tabrizi: Multiplex assay for simultaneous detection of Mycoplasma genitalium and macrolide resistance using PlexPCR
Date/time: 11 April 2016/12.30 – 13.30
- Meet-the-Expert conference session: How to diagnose and treat infections due to Mycoplasma genitalium and other emerging sexually transmitted pathogens
Date/time: 11 April 2016/07.45 – 08.45
About PlexPCR™ and ResistancePlus™
PlexPCR and ResistancePlus constitute multiplex qPCR kits for detection of infectious disease pathogens2 and antimicrobial resistance markers, respectively. Powered by the company’s proprietary PlexZyme™ and PlexPrime™ technologies, both product lines offer high multiplexing capability. All PlexPCR tests detect more pathogens and the ResistancePlus tests detect multiple genetic markers for antimicrobial resistance to provide more actionable information per test.
About Mycoplasma genitalium
Mycoplasma genitalium is a sexually transmitted infection (STI) that can cause symptoms including urethritis, cervicitis and pelvic inflammatory disease. In the general population, the prevalence of M. genitalium ranges from 1% – 3% and in higher risk populations it ranges from 10 – 40%, often exceeding that of Neisseria gonorrhoeae infection. M. genitaliuminfection has been largely under reported due to the difficulty of isolating and culturing the organism, which can take months. This difficulty means that molecular testing is the only practical method of reliably identifying M. genitalium. Antibiotic resistance to the recommended antimicrobial treatment, azithromycin, is rapidly emerging. Various government initiatives have focused on increasing the development and use of rapid molecular diagnostic tests for identifying infections and also characterizing the presence of any resistant bacteria.
Based in Sydney, Australia and founded in 2009, SpeeDx is a privately owned company that specializes in providing innovative multiplex real-time polymerase chain reaction (qPCR) solutions for clinical diagnostics. SpeeDx’s portfolio of market leading detection and priming technologies enable new healthcare paradigms that lead to improved delivery and reduced costs. SpeeDx has a proven track record of scientific discovery and strives to provide cutting edge and clinically relevant tools to the clinical diagnostic market. For more information on SpeeDx please see:http://www.speedx.com.au/.
1 The M. genitalium ResistancePlus™ Kit is for research use only (RUO), not for diagnostic use. Not for sale in USA.
2 Registration pending.